AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1461628 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 0
Study 6141926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pindolol eye-drops, twice daily
Number of subjects: 19
Study 6141926 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol eye-drops, twice daily
Number of subjects: 19
Study 30768462 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rocuronium administration (n = 58)
Number of subjects: 114
Study 30768462 — intervention group
Group type: COMPARATOR
Intervention: Late rocuronium administration (n = 56)
Number of subjects: 114
Study 29775547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beverage (NR; 12.8 mmol nitrate)
Number of subjects: 9
Study 29775547 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted placebo (PL)
Number of subjects: 9
Study 29775547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beverage (NR)
Number of subjects: 9
Study 26747859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab + Paclitaxel
Number of subjects: 665
Study 26747859 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Paclitaxel
Number of subjects: 665
Study 24119983 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Wax (BW)
Number of subjects: 50
Study 24119983 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-Soluble Wax (WSW)
Number of subjects: 50
Study 24119983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemostatic treatment)
Number of subjects: 50
Study 21843930 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical deflators
Number of subjects: 129
Study 21843930 — intervention group
Group type: COMPARATOR
Intervention: Medical deflators
Number of subjects: 129
Study 20363504 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0‐mm CICS
Number of subjects: 90
Study 20363504 — intervention group
Group type: COMPARATOR
Intervention: 3.0‐mm SICS
Number of subjects: 90
Study 20363504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0‐mm CICS
Number of subjects: 90
Study 20363504 — intervention group
Group type: COMPARATOR
Intervention: 2.0‐mm SICS
Number of subjects: 90
Study 17922725 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 40
Study 17922725 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 40
Study 16096246 — intervention group
Group type: EXPERIMENTAL
Intervention: Back to Fitness programme
Number of subjects: 237
Study 16096246 — intervention group
Group type: COMPARATOR
Intervention: Individual physiotherapy
Number of subjects: 237
Study 12386641 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated), 24 microg x kg(‐1) x h(‐1) for 96 hours
Number of subjects: 1690
Study 12386641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study 10446691 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 200 mg twice daily (group A)
Number of subjects: 42
Study 10446691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 42
Study 7768546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral typhoid vaccine (Ty21a)
Number of subjects: 6
Study 7768546 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 6
Study 2311146 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain lidocaine
Number of subjects: 20
Study 2311146 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine
Number of subjects: 20
Study 911030 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG adjuvant immunotherapy
Number of subjects: 100
Study 30343376 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted stretching (IStr)
Number of subjects: 27
Study 30343376 — intervention group
Group type: COMPARATOR
Intervention: Perineal massage (PnM)
Number of subjects: 27
Study 27225971 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 50
Study 27225971 — intervention group
Group type: COMPARATOR
Intervention: Delorme's operation
Number of subjects: 50
Study 27225971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 50
Study 25318650 — intervention group
Group type: EXPERIMENTAL
Intervention: New Forest Parenting Package (NFPP)
Number of subjects: 164
Study 25318650 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping the Noncompliant Child (HNC)
Number of subjects: 164
Study 25318650 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 164
Study 23855973 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/d of fish oil (providing 3 g of EPA + DHA)
Number of subjects: 12
Study 23855973 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn and soybean oil)
Number of subjects: 12
Study 16684856 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (9 weeks)
Number of subjects: 8
Study 16684856 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling exercise
Number of subjects: 8
Study 15085909 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Gamble (SG)
Number of subjects: 31
Study 15085909 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Trade-Off (TTO)
Number of subjects: 31
Study 15085909 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility responses for hypothetical respondents
Number of subjects: 31
Study 15085909 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing glasses (health state)
Number of subjects: 31
Study 10743982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole admixed with yogurt (regimen A)
Number of subjects: 24
Study 10743982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole admixed with Ensure pudding (regimen B)
Number of subjects: 24
Study 10743982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole admixed with cottage cheese (regimen C)
Number of subjects: 24
Study 10743982 — intervention group
Group type: COMPARATOR
Intervention: Intact lansoprazole capsule (regimen D)
Number of subjects: 24
Study 8922766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg midazolam
Number of subjects: 120
Study 8922766 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms alfentanil
Number of subjects: 120
Study 8922766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg midazolam plus 250 micrograms alfentanil
Number of subjects: 120
Study 8922766 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study 1388952 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 0
Study 1388952 — intervention group
Group type: COMPARATOR
Intervention: Mechanical oral hygiene (wooden interdental cleaner)
Number of subjects: 0
Study 3894143 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein (1 ng/kg . min infused intravenously over 15 min)
Number of subjects: 24
Study 3894143 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 24
Study 3894143 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein (i.v.)
Number of subjects: 24
Study 31593122 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm, humidified CO2 insufflation
Number of subjects: 150
Study 31593122 — intervention group
Group type: EXPERIMENTAL
Intervention: 20°C, 0% relative humidity CO2 with forced-air warmer set to 38°C
Number of subjects: 150
Study 31593122 — intervention group
Group type: COMPARATOR
Intervention: Dry CO2 insufflation (Group CE)
Number of subjects: 150
Study 27433812 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatorade and 357 g of PEG (day-prior dose)
Number of subjects: 1000
Study 27433812 — intervention group
Group type: COMPARATOR
Intervention: Split-dose bowel preparations (3 different types)
Number of subjects: 1000
Study 27433812 — intervention group
Group type: COMPARATOR
Intervention: Split-dose bowel preparations
Number of subjects: 1000
Study 26398885 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioural intervention (GET.ON Mood Enhancer)
Number of subjects: 406
Study 26398885 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care-as-usual (Control)
Number of subjects: 406
Study 26398885 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 406
Study 24874401 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSA‐LAM (1.0 µg)
Number of subjects: 90
Study 24874401 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSA‐LAM (0.1 µg)
Number of subjects: 90
Study 24874401 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCwA (1.0 µg)
Number of subjects: 90
Study 24874401 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCwA (0.1 µg)
Number of subjects: 90
Study 24874401 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSA‐LAM and MLCwA (both doses)
Number of subjects: 90
Study 24874401 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin PPD
Number of subjects: 90
Study 21862698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 11064
Study 21862698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11064
Study 19494158 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 19
Study 19494158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17223409 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of simvastatin
Number of subjects: 107
Study 17223409 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of simvastatin
Number of subjects: 107
Study 17223409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 15646229 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek with Filtek Flow lining
Number of subjects: 4
Study 15646229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Ceram with Tetric Flow lining
Number of subjects: 4
Study 15646229 — intervention group
Group type: COMPARATOR
Intervention: Filtek
Number of subjects: 4
Study 15646229 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram
Number of subjects: 4
Study 11368263 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal ovules (3-day treatment)
Number of subjects: 384
Study 11368263 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin vaginal cream (7-day treatment)
Number of subjects: 384
Study 9443537 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (5, 10 mg P.O.)
Number of subjects: 12
Study 9443537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9443537 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (2.5, 5 mg P.O.)
Number of subjects: 12
Study 9443537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripelennamine (75 mg)
Number of subjects: 12
Study 7977316 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrendipine (10 to 40 mg/d)
Number of subjects: 16
Study 7977316 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (5 to 20 mg/d)
Number of subjects: 16
Study 2686418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg intravenously every 12 hours
Number of subjects: 86
Study 2686418 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 0.5 to 2 g intravenously every eight to 12 hours
Number of subjects: 86
Study 31705581 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray combined with 2% lidocaine gel
Number of subjects: 50
Study 31705581 — intervention group
Group type: COMPARATOR
Intervention: Saline solution spray combined with 2% lidocaine gel
Number of subjects: 50
Study 31711438 — intervention group
Group type: COMPARATOR
Intervention: Conventional surface landmark‐guided midline technique (group LM)
Number of subjects: 180
Study 31711438 — intervention group
Group type: COMPARATOR
Intervention: Pre‐procedural US‐guided midline technique (group UM)
Number of subjects: 180
Study 31711438 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐procedural US‐guided paramedian technique (group UP)
Number of subjects: 180
Study 27957618 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid local injection
Number of subjects: 36
Study 27957618 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous whole blood
Number of subjects: 36
Study 27957618 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 36
Study 26070913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg every 12 hours for 24 weeks
Number of subjects: 69
Study 26070913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 26070913 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Ivacaftor
Number of subjects: 69
Study 26070913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor to Ivacaftor
Number of subjects: 69
Study 23933953 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg once daily (n = 12)
Number of subjects: 32
Study 23933953 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg once daily (n = 12)
Number of subjects: 32
Study 23933953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 32
Study 21799173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol group (aspirin plus cilostazol)
Number of subjects: 457
Study 21799173 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel group (aspirin plus clopidogrel)
Number of subjects: 457
Study 21799173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol group
Number of subjects: 457
Study 21799173 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel group
Number of subjects: 457
Study 19508931 — intervention group
Group type: EXPERIMENTAL
Intervention: Web site for weight control (used over a 12-month period)
Number of subjects: 111
Study 16847682 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurology course (low patient-related teaching)
Number of subjects: 111
Study 16847682 — intervention group
Group type: COMPARATOR
Intervention: Otolaryngology course (high patient-related teaching)
Number of subjects: 111
Study 16847682 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning styles (strategic and deep)
Number of subjects: 111
Study 15562366 — intervention group
Group type: COMPARATOR
Intervention: Canarypox vector-based HIV vaccines (ALVAC-HIV)
Number of subjects: 8
Study 12815771 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia
Number of subjects: 184
Study 12815771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed inhalation and intravenous anaesthesia
Number of subjects: 184
Study 12815771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia
Number of subjects: 184
Study 9247978 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 125
Study 9247978 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptics
Number of subjects: 125
Study 8315424 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 80 mg/m2
Number of subjects: 279
Study 8315424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 7.5 g/m2 plus Doxorubicin 60 mg/m2
Number of subjects: 279
Study 8315424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin 8 mg/m2 plus Doxorubicin 40 mg/m2 plus Cisplatin 60 mg/m2
Number of subjects: 279
Study 3554564 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg daily for the first two weeks, then three times weekly)
Number of subjects: 24
Study 3554564 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 24
Study 3554564 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution intravenously)
Number of subjects: 24
Study 30144731 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention
Number of subjects: 153
Study 30144731 — intervention group
Group type: COMPARATOR
Intervention: Self-esteem intervention
Number of subjects: 153
Study 30144731 — intervention group
Group type: COMPARATOR
Intervention: Positive distraction control
Number of subjects: 153
Study 26849410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain self-management (PSM) programme
Number of subjects: 250
Study 26849410 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 250
Study 24323178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered esophageal stent placement post-ESD (group A, n = 11)
Number of subjects: 22
Study 24323178 — intervention group
Group type: COMPARATOR
Intervention: No stent placement (group B, n = 11)
Number of subjects: 22
Study 22189383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based neoadjuvant chemotherapy (NAC)
Number of subjects: 449
Study 22189383 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy only (Control)
Number of subjects: 449
Study 22189383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based neoadjuvant chemotherapy (NAC) with complete downstaging (CD)
Number of subjects: 449
Study 20163382 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU) combined with nicotine patches plus cognitive behavioral group counseling for smoking cessation (n = 153)
Number of subjects: 225
Study 20163382 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone (n = 72)
Number of subjects: 225
Study 20054187 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (24-week duration)
Number of subjects: 54
Study 20054187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight loss intervention)
Number of subjects: 54
Study 15813708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse specialists in Parkinson's disease
Number of subjects: 1859
Study 12433010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pool Cool program (skin cancer prevention program)
Number of subjects: 0
Study 12433010 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched injury-prevention control program
Number of subjects: 0
Study 11344739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use formula
Number of subjects: 727
Study 11344739 — intervention group
Group type: COMPARATOR
Intervention: Powdered formula
Number of subjects: 727
Study 11344739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ready-to-use and powdered formulas
Number of subjects: 727
Study 8704116 — intervention group
Group type: COMPARATOR
Intervention: Intravenous calcitriol (2 micrograms after each dialysis)
Number of subjects: 0
Study 8704116 — intervention group
Group type: COMPARATOR
Intervention: Oral calcitriol (2 micrograms after each dialysis)
Number of subjects: 0
Study 2072853 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine chemoprophylaxis
Number of subjects: 61
Study 2072853 — intervention group
Group type: COMPARATOR
Intervention: No quinine chemoprophylaxis (Control)
Number of subjects: 61
Study 6414795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral long-term treatment with antiarrhythmic drugs (aprindine, mexiletine, disopyramide, amiodarone)
Number of subjects: 82
Study 6414795 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 82
Study 31919123 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of activated and expanded haploidentical NK (NKAE) cells, two doses once a week, using a GMP K562‐mbIL15‐41BBL stimulus from a haploidentical donor and interleukin 2 subcutaneously.
Number of subjects: 0
Study 30575616 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based accommodative/vergence therapy (OBAVT)
Number of subjects: 34
Study 30575616 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo therapy (OBPT)
Number of subjects: 34
Study 29078971 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with real needle penetration
Number of subjects: 0
Study 29078971 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment without needle penetration
Number of subjects: 0
Study 25730341 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoceptive exposure (IE) through running, following a 3-day group cognitive behavioral therapy intervention.
Number of subjects: 28
Study 23828333 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week standardized yoga protocol (Viniyoga tradition), 45-minute sessions once per week and home practice
Number of subjects: 9
Study 21816050 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Essential Newborn Care (ENC) training
Number of subjects: 0
Study 21816050 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Resuscitation Program (NRP) training
Number of subjects: 0
Study 21816050 — intervention group
Group type: COMPARATOR
Intervention: Before ENC training
Number of subjects: 0
Study 19183083 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine screening for intimate partner violence (IPV)
Number of subjects: 0
Study 19183083 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking about IPV in differential diagnosis
Number of subjects: 0
Study 19183083 — intervention group
Group type: COMPARATOR
Intervention: CDC randomized controlled trial
Number of subjects: 0
Study 16518519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxerutins (2 g/day)
Number of subjects: 212
Study 16518519 — intervention group
Group type: COMPARATOR
Intervention: Daflon (3 tablets of 500 mg daily for 8 weeks)
Number of subjects: 212
Study 12680524 — intervention group
Group type: EXPERIMENTAL
Intervention: HME with fresh gas flow of 1L/min
Number of subjects: 40
Study 12680524 — intervention group
Group type: EXPERIMENTAL
Intervention: HME with fresh gas flow of 3L/min
Number of subjects: 40
Study 12680524 — intervention group
Group type: COMPARATOR
Intervention: Fresh gas flow of 1L/min without HME
Number of subjects: 40
Study 12680524 — intervention group
Group type: COMPARATOR
Intervention: Fresh gas flow of 3L/min without HME
Number of subjects: 40
Study 9952054 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency in performing low‐fat eating behaviors
Number of subjects: 301
Study 9952054 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage calories from fat intake
Number of subjects: 301
Study 8669217 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 30
Study 8669217 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 30
Study 8669217 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 30
Study 2179027 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 5
Study 2179027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5